GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative ColitisPRESS RELEASE – For UK consumer health, medical and trade media onlyRisankizumab will be ...

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)Updates 2025 expected revenue range to $1.5 to 2.5 billionExpects to ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and ITM Isotope Technologies Munich ...

Rappta Therapeutics (“Rappta”), focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A), today announces an exclusive global license agreement with SpringWorks ...

Frontage Holdings Corporation (SEHK stock code: 1521) announced on January 6 2025 that Dr. Abdul Mutlib has decided to step aside from his current role as CEO of the company to facilitate the ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

Outrun Therapeutics (“Outrun”), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...